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In the contemporary practice of treatment of myocardial in-
farction (MI), beta-blocking agents have no mortality benefit
but they do reduce recurrent myocardial infarction (MI) and
angina. However, this comes at the expense of an increase in
heart failure, cardiogenic shock and drug discontinuation as
shown by a recent meta-analysis published online in the
American Journal of Medicine in June 2014 [1]. This meta-
analysis involved 60 trials with 102,003 patients and the
primary outcome was all-cause mortality. The authors con-
cluded that clinical guidelines recommending the use of beta-
blocking agents in post-MI patients need to be reconsidered.
Consequently, debate has arisen regarding the efficacy of beta-
blocking agents in MI and in other cardiovascular conditions.
Let’s review some recent trials on the application of beta-
blocking agents in patients with various cardiovascular dis-
eases and under various circumstances.
Beta-blocking agents in angina and MI
The role of beta-blockers in patients with coronary risk factors
or a remote MI or stroke has been assessed in a meta-analysis,
regrouping 44,708 patients from the Reduction of Athero-
thrombosis for Continued Health (REACH) Registry [2]. In
this observational study of patients with either risk factors
only, known prior MI, or known coronary artery disease
(CAD) without MI, the use of beta-blockers was not associ-
ated with a lower risk of composite cardiovascular events after
a 44-month median follow-up. The authors clearly pointed to
the fact that the role of beta-blocking agents for secondary
prevention in these patients should be reconsidered.
Beta-blocking agents and percutaneous coronary
intervention (PCI)
Osaza et al. [3] studied the influence of beta-blocker therapy on
prognosis in 5288 patients with CAD who underwent percuta-
neous coronary intervention (PCI). The patients had no history
ofMI or heart failure. Beta-blocker therapywas associated with
worse 3-year clinical outcomes in CAD patients who
underwent PCI. As a result, randomised trials are warranted
to identify appropriate subsets of patients who could truly
benefit from long-term use of beta-blockers in this setting.
Beta-blocking agents and heart failure
Patients with heart failure in whom there is no contraindica-
tion should receive beta-blocker therapy. This pertains cur-
rently to 120,000 patients in the Netherlands raising to
200,000 in the coming decade [4]. Results from major studies
involving bisoprolol, carvedilol, and metoprolol have demon-
strated significant morbidity and mortality benefits, with a
mortality reduction of approximately 35 % across trials. The
Study of the Effects of Nebivolol Intervention on Outcomes
and Rehospitalisation in Seniors with Heart Failure
(SENIORS) in 2128 patients aged 70 years and older with
heart failure independent of left ventricular ejection fraction at
entry demonstrated that nebivolol significantly reduced the
composite outcome of all-cause mortality and cardiovascular
hospital admission by 14 %; however, nebivolol did not
reduce the risk of all-cause mortality compared with placebo
[5]. Overall, the efficacy and tolerability of bisoprolol, carve-
dilol and metoprolol are similar in patients with systolic heart
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failure, but nebivolol is not well-tolerated and is less effective
than the other beta-blocking agents possibly due to less re-
duction in heart rate [6, 7]. Importantly, in patients with
unstable severe heart failure, substantial evidence for the use
of beta-blocking agents is lacking. In these patients temporary
lowering or discontinuation of beta-blocker therapy may be
necessary and lifesaving [8].
Beta-blocking agents and hypertension
Beta-adrenergic receptor blockers have been used for more
than 45 years in the treatment of hypertension. Recent meta-
analyses, which specifically addressed the effect of beta-
blockers in the treatment of hypertension, have confirmed
their efficacy in the reduction of cardiovascular morbidity
and mortality [9, 10]. However, the beneficial effect was
mainly seen in younger patients (<60 years) and less in older
patients. In the elderly population there is an excess risk of
stroke with beta-blockers compared with other antihyperten-
sive agents. This class of agents decreases cardiovascular
endpoints in younger patients, suggesting that age might be
a more important factor than the choice of the beta-
blocking agent.
Beta-blocking agents and coronary artery bypass grafting
Use of preoperative beta-blockers has been associated with a
reduction in perioperative mortality for patients undergoing
coronary artery bypass grafting (CABG) in observational re-
search studies. This has led to the adoption of preoperative
beta-blocker therapy as a quality standard. However, Brinkman
et al. [11] recently showed in a retrospective analysis of the
Society of Thoracic Surgeons National Adult Cardiac database
for 1107 hospitals performing CABG in the US in 506,110
patients from 2008 to 2012, that preoperative beta-blocker use
among patients undergoing CABG surgery was not associated
with improved perioperative outcomes.
Beta-blocking agents and non-cardiac surgery
The cardiovascular benefit of perioperative beta-blocker ther-
apy for patients undergoing non-cardiac surgery has been the
subject of debate for more than two decades. In recent years,
the controversy has been renewed by conflicting results of
studies that have shown both protective and harmful effects
[12]. A recent meta-analysis by Bouri et al. [13] of nine trials
including 10,529 patients demonstrated an increased risk of
30-day mortality among patients receiving a beta-blocking
agent. It has been proclaimed that using beta-blocking agents
in non-cardiac surgery - a policy previously advocated by the
European Society of Cardiology (ESC) guideline - might have
caused 10,000 iatrogenic deaths each year in the UK [14]. In
reality it is of course not known how universally the guideline
is followed, so the actual number of presumed deaths is
probably much smaller.
New guidelines on non-cardiac surgery! The inherent ESC
guideline –endorsed by our national society, the NVVC- has
recently been adapted according to current knowledge and has
been published, jointly with the European Society of Anaesthe-
siology (ESA), under the title Non-Cardiac Surgery: Cardio-
vascular Assessment & Management (Chairpersons Steen
Dalby Kristensen, Juhani Knuuti & Stefan De Hert). The
updated 112-page document with 279 references is freely
downloadable from the ESC and European Heart Journal
(EHJ) websites and was published online in the EHJ on 1
August 2014 [15]. The 2014 ESC/ESA Guidelines cover the
entire field including surgical risk assessment, preoperative
evaluation, and optimal perioperative management, and also
address relevant cardiology and anaesthesiology issues in pa-
tients with specific cardiac diseases and common comorbidities
who are scheduled to undergo non-cardiac surgery. The new
2014 ESC/ESA Guidelines state that beta-blockers are no lon-
ger recommended in patients scheduled for low or intermediate
risk surgery. The initiation of beta-blockers in patients who
undergo non-cardiac surgery should not be considered routine.
With most patients, the use of beta-blockers should be evaluat-
ed by their clinician unless specifically stated otherwise. Peri-
operative continuation of beta-blockers is recommended in
patients currently treated with beta-blockers. Preoperative initi-
ation of beta-blockers may be considered in patients scheduled
for high-risk surgery and who have ≥2 clinical risk factors or
American Society of Anesthesiologists (ASA) status ≥3 and
those who have known ischaemic heart disease or myocardial
ischaemia. Nevertheless, initiation of perioperative high-dose
beta-blockers without titration is not recommended. These
2014 Guidelines were released simultaneously with the Amer-
ican College of Cardiology/American Heart Association
Guidelines on the same topic, published in both the Journal of
the American College of Cardiology (JACC) and Circulation.
To summarise, over the past years beta-blocking agents
have gained a fixed niche in the pharmaceutical management
of patients with a variety of cardiovascular diseases. It speaks
for itself that they are here to stay. However, recent clinical
trials have been rather sceptical about the generally accepted
positive effects of these drugs in cardiovascular medicine
independent of the nature of the disease. Consequently, the
indiscriminate use of beta-blocker therapy as a panacea for
cardiovascular diseases in general should be highly discour-
aged and newly developed guidelines should reconsider its
appropriate use and be modified accordingly as has recently
been demonstrated for the use of beta-blocking agents in
patients undergoing non-cardiac surgery.
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